DDInter1702 DDInter1055
Sorafenib is a bi-aryl urea and an oral multikinase inhibitor. It targets cell surface tyrosine kinase receptors and downstream intracellular kinases that are implicated in tumour cell proliferation and tumour angiogenesis. First approved by the FDA and European Commission in 2007 for the treatment of hepatocellular carcinoma, sorafenib is also indicated to treat renal carcinoma and differentiated thyroid carcinoma.
Levofloxacin is a fluoroquinolone antibiotic and the optical S-(-) isomer of racemic [ofloxacin]. It reportedly carries 8 to 128-fold more activity against both gram-negative and gram-positive bacteria compared to R-(+)-ofloxacin and remains stereochemically stable following administration (i.e. it does not invert to the inactive isomer). Levofloxacin, along with other quinolones such as [gatifloxacin] and [moxifloxacin], is a member of the third generation of fluoroquinolones, colloquially referred to as the "respiratory quinolones" due to improved activity against gram-positive bacteria commonly implicated in respiratory infections.[A31453,A190756] Levofloxacin was first approved by the FDA in 1996, and was approved in Canada and several South American countries soon after.
Sorafenib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Gemifloxacin
Gemifloxacin {u} (Compound) resembles {v} (Compound) Levofloxacin
Sorafenib {u} may lead to a major life threatening interaction when taken with {v} Sparfloxacin
Sparfloxacin {u} (Compound) resembles {v} (Compound) Levofloxacin
Sorafenib {u} may lead to a major life threatening interaction when taken with {v} Moxifloxacin
Moxifloxacin {u} (Compound) resembles {v} (Compound) Levofloxacin
Sorafenib {u} may lead to a major life threatening interaction when taken with {v} Gatifloxacin
Gatifloxacin {u} (Compound) resembles {v} (Compound) Levofloxacin
Sorafenib {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Levofloxacin
Sorafenib {u} (Compound) downregulates {v} (Gene) TOP2A
TOP2A {u} (Gene) is bound by {v} (Compound) Levofloxacin
Sorafenib {u} (Compound) upregulates {v} (Gene) SELL
SELL {u} (Gene) is upregulated by {v} (Compound) Levofloxacin
Sorafenib {u} (Compound) upregulates {v} (Gene) TRIB3
TRIB3 {u} (Gene) is downregulated by {v} (Compound) Levofloxacin
Sorafenib {u} (Compound) downregulates {v} (Gene) SNX7
SNX7 {u} (Gene) is downregulated by {v} (Compound) Levofloxacin
Sorafenib {u} (Compound) causes {v} (Side Effect) Dysphagia
Dysphagia {u} (Side Effect) is caused by {v} (Compound) Levofloxacin
Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Gemifloxacin and Gemifloxacin (Compound) resembles Levofloxacin (Compound)
Sorafenib may lead to a major life threatening interaction when taken with Sparfloxacin and Sparfloxacin (Compound) resembles Levofloxacin (Compound)
Sorafenib may lead to a major life threatening interaction when taken with Moxifloxacin and Moxifloxacin (Compound) resembles Levofloxacin (Compound)
Sorafenib may lead to a major life threatening interaction when taken with Gatifloxacin and Gatifloxacin (Compound) resembles Levofloxacin (Compound)
Sorafenib (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Levofloxacin (Compound)
Sorafenib (Compound) downregulates TOP2A (Gene) and TOP2A (Gene) is bound by Levofloxacin (Compound)
Sorafenib (Compound) upregulates SELL (Gene) and SELL (Gene) is upregulated by Levofloxacin (Compound)
Sorafenib (Compound) upregulates TRIB3 (Gene) and TRIB3 (Gene) is downregulated by Levofloxacin (Compound)
Sorafenib (Compound) downregulates SNX7 (Gene) and SNX7 (Gene) is downregulated by Levofloxacin (Compound)
Sorafenib (Compound) causes Dysphagia (Side Effect) and Dysphagia (Side Effect) is caused by Levofloxacin (Compound)